Avecho Biotechnology (ASX:AVE) and Sandoz have signed an exclusive ten-year development and licensing agreement for the commercial rights to the Australian company's phase 3 cannabidiol capsule for insomnia in Australia.
Sandoz backs Australian medicinal cannabis company in ten-year agreement
March 3, 2025 BioPharmaAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 12 December
December 12, 2025 - - Podcast -
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech
